GammaTile

GammaTile® Therapy is FDA-cleared as a treatment for patients with newly diagnosed malignant intracranial neoplasms and patients with recurrent intracranial neoplasms, including brain metastases, glioblastomas, and meningiomas.

Arizona Center for Cancer Care (AZCCC) announced its 100^th patient treated with GammaTile® Therapy, a Surgically Targeted Radiation Therapy (STaRT) for brain tumors.

Arizona Center for Cancer Care is a multispecialty practice that provides care to more than 30,000 patients across the Phoenix metropolitan area, with a commitment to offering their community the most comprehensive cancer treatments. Implementing a GammaTile Therapy program shows their dedication to providing their patients with the most innovative oncology technologies that are available.  

“GammaTile has given us the ability to offer safe and effective treatment to patients who otherwise would have limited options. Over the last 100 cases, our multidisciplinary collaborative team of neurosurgeons, neuro-oncologists, and radiation oncologists has furthered our understanding and mastery of this technology to optimize care for patients,” said Steven Sckolnik, MD, radiation oncologist at Arizona Center for Cancer Care.  “I am looking forward to the future as the role of this therapy grows and provides more dynamic solutions for the oncology community.”

GammaTile has been available in the United States since 2019 for patients with  recurrent brain tumors and since January 2020 for patients with newly-diagnosed malignant brain tumors. GammaTile is a game-changing treatment that is implanted in the last five minutes of brain tumor removal surgery to eliminate residual tumor cells. This targeted therapy replaces the need for weeks of external radiation treatments, allowing patients the freedom to resume their normal lives and activities more quickly than current standards of care. Clinical studies have shown that treatment with GammaTile significantly delays tumor regrowth and can extend the lives of patients undergoing treatment for the deadliest form of brain cancer, glioblastoma.  

“This is truly a special milestone marking the 100^th patient treated with GammaTile, showing Arizona Center for Cancer Care’s devotion to their patients in providing the most advanced treatment options available,” said Matt Likens, president, and CEO of GT Medical Technologies. “We are honored to partner with their entire care team including neurosurgery, radiation oncology, and medical physics—all departments collaborating together to make sure patients are getting the best treatment.”  

How GammaTile Therapy Works

About Arizona Center for Cancer Care 

Arizona Center for Cancer Care (AZCCC) is a multispecialty physician cooperative devoted to the treatment and care of patients with cancer. We began in 2008 with a small core of practitioners dedicated to the proposition that patients come first. Our mission is to be partners in our patient’s care. That care must be the best, and involves the pinnacle of treatment standards, access to research, and passion for a cure. We partner with HonorHealth, and other community resources to provide the very best chances for our patients. Our goal is to cure, when possible, extend life when desired, and support quality of living always. Unique in its philosophy and goals, AZCCC has grown to be the largest, and strives to be the best, cancer support network in Arizona. For more information visit ArizonaCCC.com. 

About GT Medical Technologies, Inc.

Driven to raise the standard of care and improve the lives of patients with brain tumors, a team of brain tumor specialists formed GT Medical Technologies with the purpose of improving the lives of patients with brain tumors.  FDA-cleared GammaTile is Surgically Targeted Radiation Therapy (STaRT) to treat patients with all types of newly diagnosed malignant and recurrent brain tumors.  This “one and done” treatment eliminates the need for one-to-six weeks of daily external beam radiation therapy, allowing patients to go about their daily lives, without the burden of additional trips to the hospital or clinic for ongoing treatment. Since beginning full market release in the United States in March 2020, GammaTile® is offered in eighty hospitals with more centers being added each month.   For more information, visit www.gtmedtech.com and follow @GammaTile on Twitter and LinkedIn.